AOA
0.003
50%
BOC
0.575
-50%
BUY
0.003
50%
TR2
0.34
-44.3%
ENL
0.033
43.5%
BLZ
0.002
-33.3%
ALM
0.007
40%
1AD
0.003
-25%
FBR
0.004
33.3%
C7A
0.003
-25%
AAU
0.01
25%
CTN
0.003
-25%
AUR
0.02
25%
RLC
0.003
-25%
MTM
0.855
24.8%
M2M
0.013
-23.5%
LM1
0.185
23.3%
IS3
0.018
-21.7%
SPQ
0.011
22.2%
EPM
0.015
-21.1%
PHX
0.14
21.7%
NFM
0.02
-20%
NHE
0.045
21.6%
OEL
0.004
-20%
PLC
0.006
20%
FMR
0.275
-16.7%
SHN
0.02
17.6%
KOB
0.06
-16.7%
AS2
0.014
16.7%
DY6
0.115
-14.8%
SIO
0.14
16.7%
MGU
0.006
-14.3%
ATC
0.029
16%
WLD
0.012
-14.3%
RLF
0.074
15.6%
ZMM
0.006
-14.3%
IMI
0.015
15.4%
HWK
0.025
-13.8%
PTX
0.062
14.8%
NVQ
0.02
-13%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CMH Clinical trial openfor enrollment

Chimeric Therapeutics (ASX:CHM), Australian leader in cell therapy, announces the Phase 18 ADVENT-AML clinical trial for patients with newly diagnosed Acute Myeloid Leukaemia is now open to enrolment at The University of Texas MD Anderson Cancer Center https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02762504-2A1499759